VSL#3® Capsules for the dietary management of Irritable Bowel Syndrome (IBS)

VSL#3® is the advanced probiotic that provides dietary support to help manage IBS1

VSL#3® has a safety profile that you and your patients can trust

In 18 different studies, VSL#3® was demonstrated to be safe—with a low incidence of minor side effects, similar to placebo.*2-19

*Studies included dietary management with VSL#3® for ulcerative colitis, irritable bowel syndrome, and pouchitis.

Reference: 1. VSL#3® Product Information. Alfasigma USA, Covington, LA. 2017. 2. Biblioni R, Fedorak RN, Tannock GW, et al. Am J Gastroenterol. 2005;100(7):1539-1546. 3. Gionchetti P, Rizzello F, Venturi A, et al. Gastroenterology. 2000;119(2):305-309. 4. Gionchetti P, Rizzello F, Helwig U, et al. Gastroenterology. 2003;124:1202-1209. 5. Huynh HQ, deBruyn J, Guan L, et al. Inflamm Bowel Dis. 2009;15(5):760-768. 6. Miele E, Pascarella F, Giannetti E, et al. Am J Gastroenterol. 2009;104:437-443. 7. Mimura T, Rizzello F, Helwig U, et al. Gut. 2004;53:108-114. 8. Rohatgi S, Ahuja V, Makharia GK, et al. BMJ Open Gastro. 2015:1-9. 9. Sood A, Midha V, Makharia GK, et al. Clin Gastroenterol Hepatol. 2009;7:1202-1209. 10. Tursi A, Brandimarte G, Giorgetti GM, et al. Med Sci Monit. 2004;10(11):PI126-PI131. 11. Tursi A, Brandimarte G, Giorgetti GM, et al. Int J Colorectal Dis. 2007;22:1103-1108. 12. Tursi A, Brandimarte G, Papa A, et al. Am J Gastroenterol. 2010;105:2218-2227. 13. Venturi A, Gionchetti P, Rizzello F, et al. Aliment Pharmacol Ther. 1999;13:1103-1108. 14. Guandalini S, Magazzu G, Chiaro A, et al. J Pediatr Gastroenterol Nutr. 2010;51(1):24-30. 15. Kim HJ, Camilleri M, McKinzie S, et al. Aliment Pharmacol Ther. 2003;17(7):895-904. 16. Kim HJ, Vazquez Roque MI, Camilleri M, et al. Neurogastroenterol Motil. 2005;17(5):687-696. 17. Kim S-E, Choi SC, Park KS, et al. J Neurogastroenterol Motil. 2015;21(1):111-120. 18. Michail S, Kenche H. Probiotics Antimicrob Proteins. 2011;3(1):1-7. 19. Wong RK, Yang C, Song G-H, et al. Dig Dis Sci. 2015:60(1):186-194.